NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

關節內粘稠補充療法市場-成長,趨勢,預測(2020年∼2025年)

Viscosupplementation Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence Pvt Ltd 商品編碼 946280
出版日期 內容資訊 英文 110 Pages
商品交期: 2-3個工作天內
價格
關節內粘稠補充療法市場-成長,趨勢,預測(2020年∼2025年) Viscosupplementation Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年06月01日內容資訊: 英文 110 Pages
簡介

關節內粘稠補充療法市場在2020年∼2025年的預測期間內,預計以5.8%左右的年複合成長率成長。帶動市場成長的要素,是罹患骨關節炎的患者增加。骨關節炎的盛行率的上升推動在預測期間內的市場成長。

本報告提供關節內粘稠補充療法市場調查,市場概要,市場成長要素及阻礙因素分析,各劑量、各終端用戶、各地區的市場規模的變化與預測,競爭情形,主要企業的簡介,市場機會等全面性資訊。

目錄

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 市場成長要素
    • 罹患骨關節炎的患者數上升
    • 先進的組合產品的引進
  • 市場阻礙因素
    • 法規上的問題和意識的缺乏
  • 波特的五力分析

第5章 市場細分化

  • 各劑量
    • 單回注射
    • 3次注射
    • 5次注射
  • 各終端用戶
    • 醫院
    • 門診病人手術中心
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Anika Therapeutics, Inc.
    • Bioventus LLC
    • Chugai Pharmaceuticals Co., Ltd. (Roche)
    • Ferring Pharmaceuticals
    • Fidia Farmaceutici spa
    • Mylan NV
    • OrthogenRx Inc.
    • Sanofi SA
    • Seikagaku Corporation

第7章 市場機會及未來趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 69923

The Viscosupplementation market studied is anticipated to grow with a CAGR of nearly 5.8%, during the forecast period.

  • Certain factors that are driving the market growth include rising patient pool suffering from osteoarthritis, along with the introduction of advanced and combination products.
  • Osteoarthritis refers to the inflammation of a joint. When joints are inflamed they can develop stiffness, warmth, swelling, redness, and pain. There are over 100 types of arthritis, namely osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, lupus, gout, pseudogout. Rheumatoid arthritis is an autoimmune disorder that causes pain and inflammation in the joints of the body. Rheumatoid arthritis disease mostly affects the joints of the hand, wrists, elbows, knees, and ankles. Results of the Global Burden of Diseases, Injuries, and Risk Factors (GBD) 2017 study indicated that there were 19,965,115 globally prevalent cases of RA in 2017 (95% uncertainty interval [UI], 17,990,489-21,995,673 cases), with an age-standardized prevalence rate of 246.6 cases/100,000 population, which increased by 7.4% between 1990 and 2017. The rising prevalence of osteoarthritis is expected to fuel the market growth over the forecast period.

Key Market Trends

Ambulatory Surgical Centers show Lucrative Opportunity in the Global Viscosupplementation Market

  • Ambulatory surgical center means a facility, located in or apart from a hospital, that provides, under the direction of a licensed physician, either diagnosis or treatment, or both, to ambulatory patients in need of medical, surgical, or mental care.
  • Throughout the past few decades, the treatment of various chronic diseases has been increasingly prioritized by the global health community or governments even in low- and middle-income countries. As a result, the demand for proper treatment and cure has risen significantly, in order to address the global osteoarthritis burden, thus leading to a rise in the utilization and adoption of Viscosupplementation.
  • Over the past few years, with the move to value-based care, hospitals and healthcare systems are facing extreme competition from outpatient service sites, particularly those which offer physician office-based procedures, and ambulatory surgery. Gaining in popularity across the globe, outpatient facilities provide both operational and economic efficiencies, enabling ease of patient access, very competitive pricing, and increased opportunities for physician engagement. Hence, owing to all the aforementioned factors, the studied market is expected to increase in the future.

Asia-Pacific is expected to Witness High Growth Rate in the Global Viscosupplementation Market

  • The Asia-Pacific market is anticipated to witness high growth during the forecast period, due to increasing healthcare expenditure. Additionally, the low cost of manufacturing in China and India has resulted in the rise in the production facilities, attracting pharmaceutical and biotechnological giants to the Asia-Pacific region from across the world.
  • The increase in the incidence of rheumatoid arthritis disease is also expected to propel the market growth in the region during the forecast period. For example, according to the Institute for Health Metrics and Evaluation, the number of cases of rheumatoid arthritis has increased from 183,272 in 2007 to 263,365 in 2017 only in India. Therefore, analyzing the number of cases in other major countries of the Asia Pacific region, the healthcare activities in relation to the treatment of rheumatoid arthritis will propel the growth of the market.

Competitive Landscape

The global Viscosupplementation market is competitive and consists of a few major players. Companies like Anika Therapeutics, Inc., Bioventus LLC, Chugai Pharmaceuticals Co., Ltd., Ferring Pharmaceuticals, Fidia Farmaceutici s.p.a., Mylan N.V., OrthogenRx Inc., Sanofi SA, Seikagaku Corporation., among others, hold the substantial market share in the market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Patient Pool Suffering from Osteoarthritis
    • 4.2.2 Introduction of Advanced and Combination Products
  • 4.3 Market Restraints
    • 4.3.1 Regulatory Issues and Lack of Awareness
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Dosage
    • 5.1.1 Single Injection
    • 5.1.2 Three Injection
    • 5.1.3 Five Injection
  • 5.2 By End-User
    • 5.2.1 Hospitals
    • 5.2.2 Ambulatory Surgical Centers
    • 5.2.3 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Anika Therapeutics, Inc.
    • 6.1.2 Bioventus LLC
    • 6.1.3 Chugai Pharmaceuticals Co., Ltd. (Roche)
    • 6.1.4 Ferring Pharmaceuticals
    • 6.1.5 Fidia Farmaceutici s.p.a.
    • 6.1.6 Mylan N.V.
    • 6.1.7 OrthogenRx Inc.
    • 6.1.8 Sanofi SA
    • 6.1.9 Seikagaku Corporation

7 MARKET OPPORTUNITIES AND FUTURE TRENDS